If this message does not appear correctly, click this link


Speeches & Conferences

July 21-22   ACT Genomics introduces precision medicine in lung cancer workshop

Air pollution has led to more lung cancer cases. How do we treat lung cancer more effectively through genomic profiling service? A lung cancer workshop is held by Taiwan Society of Pulmonary and Critical Care Medicine in Taichung to explore the latest trend in lung cancer treatment. ACT Genomics will share more about precision medicine in our display area and provide information on cancer genomic profiling services to physicians.


June 15-16  ACT Genomics Roundtable & Symposium Talk in Cebu, Philippines

ACT Genomics is honoured to be invited to give a roundtable & symposium talk in Cebu, Philippines. During this trip, our Medical Liaison Dr. Liisa Nairismägi will be discussing topics on “How to Utilize Comprehensive Genomic Profiling for Cancer Management in a Clinical Setting” & “The Role of Comprehensive Genomic Profiling in Cancer Management in the Era of Precision Medicine” respectively.


June 13-14  ACT Genomics is awarded the best immunotherapy solution provider in 2nd China & America Precision Medicine Forum 2018

ACT Genomics is awarded the best immunotherapy solution provider in 2nd China & America Precision Medicine Forum 2018 for its research achievements in immunotherapy. ACT Genomics CSO Dr. Shu-Jen Chen will deliver a talk to elaborate on the role and application of precision medicine in immunotherapy, and discuss how to evaluate the use of immune check point inhibitor based on TMB and MSI calculation. http://www.cdmc.org.cn/2018/pmf/

Image title


June 11-13  Shed light on tumor microenvironment in Biomarker & Immuno-oncology World Congress

The 2018 Biomarker & Immuno-oncology World Congress in Boston brings together biopharma, molecular diagnostics companies and research institutes to discuss the development of biomarkers for immunotherapy. On June 11th, Dr. Kien Thiam Tan will present our newly developed TME (tumor microenvironment) profiling service, aimed to identify patients suitable for immune checkpoint inhibitors. Visit us at booth #2 to find out how our TME profiling service and ACTOnco® comprehensive genomic profiling can accelerate cancer drug development!     http://www.biomarkerworldcongress.com/

Image title


June 03  ACT Genomics introduced precision medicine in Taiwan Bio Forum

ACT Genomics is honoured to introduce precision medicine in Taiwan Bio Forum co-organized by The Development Center for Biotechnology (DCB) and Monte Jade Science and Technology Association of New England (MJNE) in Boston. Hope more ideas can be generated in this international multidisciplinary session.

Image title


June 01-05 ACT Genomics research results accepted by 2018 ASCO

ACT Genomics is proud to have 4 abstracts accepted for publication at 2018 ASCO! The abstracts highlight our experiences in identifying actionable alterations across different solid tumors using comprehensive genomic profiling, as well as experiences in utilizing hot-spot panel to guide lung cancer therapy.

Image title


May 28  Precision oncology – searching for the most effective cancer treatment

The health education talk to the general public at the Hong Kong Central Library on May 28th, 2018 was a success. Dr. Amy Chang gave a thorough presentation to emphasize that Next-Generation Sequencing (NGS) tests could become a new benchmark in early cancer diagnosis. As targeted and immune drugs are becoming more popular, Dr. Chang aims to raise awareness on NGS as an important diagnostic tool for selecting suitable drug candidates. Dr. Chang also quoted a few examples of clinical cases using NGS. Strong audience interest was provoked to ask many stimulating questions and informative answers were provided.

Image title


May 26 -27 The 2nd Guangdong-Hong Kong-Macao Thoracic Cancers Symposium

ACT Genomics was invited to participate in the two-day Guangdong-Hong Kong-Macao Thoracic Cancers Symposium on May 26th and 27th in Shenzhen, China. The symposium focused on lung cancer surgery and treatment, and it exemplified the Greater Bay Area initiative. ACT Genomics was honoured to be the only genomics company attending the symposium. This experience has allowed connections to be made with oncologists and surgeons in Guangdong and Macau in addition to Hong Kong.

Image title


May 16  Molecular Grand Round – Li Ka Shing Faculty of Medicine, HKU and Gleneagles HK Hospital

The Molecular Grand Round – Initial Experience Sharing on NGS-Guided Oncology Practice” was held on May 16th, 2018. The event was co-organized by the Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong and Gleneagles HK Hospital, and sponsored by ACT Genomics. The Molecular Grand Round was very successful, and we received many positive feedbacks. The face-to-face case sharing experience on molecular genetics and genomics was one of its kind in Hong Kong and even worldwide. It reinforced the significance of using NGS as a diagnostic technique for precision medicine in oncology. The enthusiastic audience and speakers are anticipating for the next Molecular Grand Round. This opportunity allows us to further promote precision oncology to the Hong Kong medical community.

Image title


May 16  ACT Genomics Scientific Talk at Sarawak General Hospital

ACT Genomics is honoured to be invited to give a scientific talk at Sarawak General Hospital. Dr. Liisa shared her insights on “The Role of Comprehensive Genomic Profiling in Cancer Management in the Era of Precision Medicine.”

Image title


May 09  Hong Kong Trade and Development Council – Hong Kong International Medical Devices and Supplies Fair

ACT Genomics was invited to participate at the 9th Hong Kong International Medical Devices and Supplies Fair held from May 7th to 9th at the Hong Kong Convention and Exhibition Centre, organized by the Hong Kong Medical and Healthcare Device Industries Association (HKMHDIA). The fair created an interactive network between healthcare providers. ACT Genomics took the opportunity to establish potential future collaborations. Dr. Bernard Chan, the Under Secretary for Commerce and Economic Development, visited our booth with Ms. Maria Chiang, Vice Chairman of HKMHDIA. ACT Genomics took the opportunity to introduce our company and technology to the visitors and exhibitors within the healthcare sector. In addition, Dr. Timothy Yip presented a talk in the medical forum on how Next-Generation Sequencing can lead to personalized medicine, and this talk was able to promote this advanced approach in cancer management to the general public.

Image title


May 08  Health Education Talk – Personalized Treatment of Lung Cancer and Psychology of Cancer Care

The health education talk by Dr. Sze Wing Kin and Dr. Maya Ho on May 8th, 2018 at the Hong Kong Cultural Centre was organized by Health Action and sponsored by ACT Genomics. Dr. Sze highlighted the roles of targeted and immune drugs in cancer therapy. The effectiveness of Next-Generation Sequencing technology to determine suitable drug targets was addressed. Subsequently, Dr. Ho elaborated on the importance of psychology in cancer care. The talk finished with a much anticipated Q&A session.

Image title


May 03  ACT Genomics shared insights in Industry Roundtable Series

The Industry Roundtable Series is a platform for in-depth discussion and exchange of knowledge amongst clinicians, researchers and industry experts. Centred on a series of topics, the Industry Roundtable harnesses the university’s innovation resources to uncover the next big trend. This Industry Roundtable Event topic “Next Generation Sequencing: The Future of Diagnostics” highlights the breadth of next generation sequencing applications and the importance of these insights in enhancing our understanding disease development as well as provide new diagnostic and treatable markers for translation into the clinic to improve patient care and survival. Dr. Allen is honoured to be one of the key speaker of Industry Roundtable Series by NUS Enterprise discussing on topic “Precision in whose terms: The Reliability & Challenges of Using NGS in Precision Medicine”. Other invited speakers include Dr. Roger Foo (Senior Consultant , NUS, Senior Investigator, CRI & GIS) and Dr. Lewis Hong (Director, Translational Biomarkers, MSD). https://www.eventnook.com/event/nusenterprise-futurehealth

Image title



Media

ACT Genomics Singapore featured in Asia-Pacific Biotech News (APBN) magazine June 2018 issue

ACT Genomics Singapore is honoured to be featured in Asia-Pacific Biotech News (APBN) magazine June 2018 issue, with features article titled “Clinical Utility of and Access to Cancer Molecular Diagnostics in Asia”. Dr Allen Lai & Dr Liisa sharing how molecular diagnostics can or cannot transform the care for cancer patients in Asia.

Image title

Full article : https://drive.google.com/file/d/1_psZN5-P-5GPuyuikAyGyH2BwgAmgnFY/view


Image title

Circulating tumor DNA is a tool for disease monitoring in patients with pancreatic cancer

Abstract : There are different treatments for metastatic pancreatic cancer patients. Therefore, disease monitoring is important for selecting effective treatments. This study indicated that circulating tumor DNA is an effective tool for disease monitoring in patients with pancreatic cancer.   See more...


Image title

Potential druggable mutations can be identified by circulating tumor DNA in advanced hepatocellular carcinoma

Abstract : In this study, next generation sequencing (68 genes) was used to detect ctDNA in 14 patients with advanced HCC. The data indicated that ctDNA is an alternative tool for getting genetic information, and have the potential for targeted treatment selection in advanced HCC.  See more...


Image title

Frontline pembrolizumab combination improves survival in metastatic lung cancer

Abstract : Combining pembrolizumab with chemotherapy in the frontline setting significantly prolonged overall and progression-free survival in previously untreated metastatic non-squamous lung cancer without EGFR or ALK mutations, according to an international phase 3 clinical trial.  See more...


Image title

Mutation burden as a predictive biomarker in first-line immunotherapy for NSCLC

Abstract : A study showed that in NSCLC patients with high mutation burden, nivolumab plus ipilimumab significantly improved progression-free survival than chemotherapy.  See more...


Image title

New genes found related to hereditary diffuse gastric cancer

Abstract : It is difficult to do a risk assessment or risk-reducing surgery in patients with hereditary diffuse gastric cancer who do not carry a CDH1 pathogenic variant, due to limited data availability. This study aimed to identify new genes associated with the disease, and found gene PALB2 may play an important role. See more...

Please do not reply to this email as it is sent from a non-monitored account. To contact us, please email service@actgenomics.com.

  To unsubscribe, please enter your E-Mail :